Literature DB >> 22083058

Effects of pravastatin on mediators of vascular function in a mouse model of soluble Fms-like tyrosine kinase-1-induced preeclampsia.

Karin A Fox1, Monica Longo, Esther Tamayo, Talar Kechichian, Egle Bytautiene, Gary D V Hankins, George R Saade, Maged M Costantine.   

Abstract

OBJECTIVE: We sought to investigate the mechanisms of action by which pravastatin improves vascular reactivity in a mouse model of preeclampsia induced by overexpression of soluble Fms-like tyrosine kinase-1 (sFlt)-1. STUDY
DESIGN: Pregnant CD-1 mice were randomly allocated to tail vein injection with adenovirus carrying sFlt-1 or murine immunoglobulin G2 Fc (control), and thereafter to receive pravastatin (5 mg/kg/d) or water. Mice were sacrificed at gestational day 18. Protein expression of endothelial nitric oxide synthase (eNOS), vascular endothelial growth factor receptor-1, and hemeoxygenase-1 were assayed by Western blot in aorta, liver, and kidneys. Serum total cholesterol concentrations were measured.
RESULTS: Pravastatin up-regulated eNOS expression in the aorta of sFlt-1 mice by nearly 2-fold (P = .005) to levels similar to control mice. Total cholesterol levels, vascular endothelial growth factor receptor-1, and hemeoxygenase-1 protein expression were similar across groups.
CONCLUSION: Pravastatin prevents vascular dysfunction in part by up-regulation of eNOS in the vasculature. Our data support a role for statins in preeclampsia prevention.
Copyright © 2011 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22083058     DOI: 10.1016/j.ajog.2011.06.083

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  26 in total

1.  Apheresis to Treat Preeclampsia: Insights, Opportunities and Challenges.

Authors:  Thomas R Easterling
Journal:  J Am Soc Nephrol       Date:  2015-09-24       Impact factor: 10.121

2.  Role of the efflux transporters BCRP and MRP1 in human placental bio-disposition of pravastatin.

Authors:  Marjan Afrouzian; Rabab Al-Lahham; Svetlana Patrikeeva; Meixiang Xu; Valentina Fokina; Wayne G Fischer; Sherif Z Abdel-Rahman; Maged Costantine; Mahmoud S Ahmed; Tatiana Nanovskaya
Journal:  Biochem Pharmacol       Date:  2018-09-12       Impact factor: 5.858

Review 3.  Residual vascular dysfunction in women with a history of preeclampsia.

Authors:  Anna E Stanhewicz
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2018-08-22       Impact factor: 3.619

4.  Pravastatin to prevent recurrent fetal death in massive perivillous fibrin deposition of the placenta (MPFD).

Authors:  Tinnakorn Chaiworapongsa; Roberto Romero; Steven J Korzeniewski; Piya Chaemsaithong; Edgar Hernandez-Andrade; James H Segars; Alan H DeCherney; M Cathleen McCoy; Chong Jai Kim; Lami Yeo; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2015-04-20

5.  Safety and pharmacokinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: a pilot randomized controlled trial.

Authors:  Maged M Costantine; Kirsten Cleary; Mary F Hebert; Mahmoud S Ahmed; Linda M Brown; Zhaoxia Ren; Thomas R Easterling; David M Haas; Laura S Haneline; Steve N Caritis; Raman Venkataramanan; Holly West; Mary D'Alton; Gary Hankins
Journal:  Am J Obstet Gynecol       Date:  2015-12-23       Impact factor: 8.661

Review 6.  Novel Interventions for the Prevention of Preeclampsia.

Authors:  Marwan Ma'ayeh; Kara M Rood; Douglas Kniss; Maged M Costantine
Journal:  Curr Hypertens Rep       Date:  2020-02-12       Impact factor: 5.369

7.  Should We Add Pravastatin to Aspirin for Preeclampsia Prevention in High-risk Women?

Authors:  Caroline C Marrs; Maged M Costantine
Journal:  Clin Obstet Gynecol       Date:  2017-03       Impact factor: 2.190

8.  Pravastatin attenuates hypertension, oxidative stress, and angiogenic imbalance in rat model of placental ischemia-induced hypertension.

Authors:  Ashley J Bauer; Christopher T Banek; Karen Needham; Haley Gillham; Susan Capoccia; Jean F Regal; Jeffrey S Gilbert
Journal:  Hypertension       Date:  2013-03-04       Impact factor: 10.190

Review 9.  Angiogenic factors in diagnosis, management, and research in preeclampsia.

Authors:  Sarosh Rana; S Ananth Karumanchi; Marshall D Lindheimer
Journal:  Hypertension       Date:  2013-10-28       Impact factor: 10.190

Review 10.  Hypertension in pregnancy: natural history and treatment options.

Authors:  L Foo; J Tay; C C Lees; C M McEniery; I B Wilkinson
Journal:  Curr Hypertens Rep       Date:  2015-05       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.